**Supplementary Fig. 4. Forest plot of combined SVR rate of SOF/VEL regimen in the treatment of decompensated and compensated hepatitis C cirrhosis patients.** There was no statistical difference between the combined SVR and the decompensated phase of SOF/VEL regimen in the treatment of patients with compensated liver cirrhosis (93.2%, 95% CI: 83.4% - 99.1% vs. 90.3%, 95% CI: 88.1% - 92.2%, *p*=0.5238). SOF, sofosbuvir; VEL, velpatasvir; RBV, ribavirin; DC, decompensated cirrhosis; CC, compensatory cirrhosis; SVR, sustained virologic response.

